ID   TYK-nu.CP-r
AC   CVCL_3221
AS   CVCL_EQ58
SY   TYK-nu (R); TYKNU CPR; TYKnuCPr; TYK-nu-CisR; Tyk-nu-cisR; TYKnuCisR; TyknuCisR
DR   EFO; EFO_0006767
DR   ArrayExpress; E-MTAB-2706
DR   cancercelllines; CVCL_3221
DR   CGH-DB; 383-2
DR   CGH-DB; 9360-4
DR   EGA; EGAS00001000610
DR   GEO; GSM851947
DR   JCRB; JCRB0234.1
DR   PharmacoDB; TYKnu_CPr_1615_2019
DR   PRIDE; PXD003668
DR   Wikidata; Q54973462
RX   PubMed=2647872;
RX   PubMed=11330945;
RX   PubMed=12417041;
RX   PubMed=22710073;
RX   PubMed=25485619;
RX   PubMed=26589293;
RX   PubMed=27561551;
CC   Population: Japanese.
CC   HLA typing: A*02:01,26:03; B*35:08,58:05; C*03:03,07:02; DRB1*13:07,15:01 (PubMed=26589293).
CC   Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP).
CC   Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Homozygous (from parent cell line).
CC   Omics: Deep proteome analysis.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Omics: Transcriptome analysis by RNAseq.
ST   Source(s): JCRB; PubMed=22710073
ST   Amelogenin: X
ST   CSF1PO: 12
ST   D13S317: 10,11
ST   D16S539: 9,10
ST   D18S51: 13
ST   D19S433: 14.2
ST   D21S11: 32.2
ST   D2S1338: 18,24
ST   D3S1358: 15
ST   D5S818: 12,13
ST   D7S820: 10
ST   D8S1179: 10,15
ST   FGA: 24
ST   TH01: 9
ST   TPOX: 9,11
ST   vWA: 14,16
DI   NCIt; C105555; High grade ovarian serous adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_1776 ! TYK-nu
SX   Female
AG   38Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 05-10-23; Version: 24
//
RX   PubMed=2647872;
RA   Yoshiya N., Adachi S., Misawa Y., Yuzawa H., Honda T., Kanazawa K.,
RA   Takeuchi S., Tanaka K.;
RT   "Isolation of cisplatin-resistant subline from human ovarian cancer
RT   cell line and analysis of its cell-biological characteristics.";
RL   Nihon Sanka Fujinka Gakkai Zasshi 41:7-14(1989).
//
RX   PubMed=11330945; DOI=10.1006/gyno.2001.6132;
RA   Watanabe T., Imoto I., Kosugi Y., Ishiwata I., Inoue S., Takayama M.,
RA   Sato A., Inazawa J.;
RT   "A novel amplification at 17q21-23 in ovarian cancer cell lines
RT   detected by comparative genomic hybridization.";
RL   Gynecol. Oncol. 81:172-177(2001).
//
RX   PubMed=12417041; DOI=10.1111/j.1349-7006.2002.tb01213.x;
RA   Watanabe T., Imoto I., Katahira T., Hirasawa A., Ishiwata I., Emi M.,
RA   Takayama M., Sato A., Inazawa J.;
RT   "Differentially regulated genes as putative targets of amplifications
RT   at 20q in ovarian cancers.";
RL   Jpn. J. Cancer Res. 93:1114-1122(2002).
//
RX   PubMed=22710073; DOI=10.1016/j.ygyno.2012.06.017;
RA   Korch C.T., Spillman M.A., Jackson T.A., Jacobsen B.M., Murphy S.K.,
RA   Lessey B.A., Jordan V.C., Bradford A.P.;
RT   "DNA profiling analysis of endometrial and ovarian cell lines reveals
RT   misidentification, redundancy and contamination.";
RL   Gynecol. Oncol. 127:241-248(2012).
//
RX   PubMed=25485619; DOI=10.1038/nbt.3080;
RA   Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z.-S.,
RA   Liu H.-B., Degenhardt J., Mayba O., Gnad F., Liu J.-F., Pau G.,
RA   Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M.-M., Zynda G.J.,
RA   Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L.,
RA   Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J.,
RA   Settleman J., Seshagiri S., Zhang Z.-M.;
RT   "A comprehensive transcriptional portrait of human cancer cell
RT   lines.";
RL   Nat. Biotechnol. 33:306-312(2015).
//
RX   PubMed=26589293; DOI=10.1186/s13073-015-0240-5;
RA   Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P.,
RA   Loewer M., Sahin U., Castle J.C.;
RT   "TCLP: an online cancer cell line catalogue integrating HLA type,
RT   predicted neo-epitopes, virus and gene expression.";
RL   Genome Med. 7:118.1-118.7(2015).
//
RX   PubMed=27561551; DOI=10.1038/ncomms12645;
RA   Coscia F., Watters K.M., Curtis M., Eckert M.A., Chiang C.Y.,
RA   Tyanova S., Montag A., Lastra R.R., Lengyel E., Mann M.;
RT   "Integrative proteomic profiling of ovarian cancer cell lines reveals
RT   precursor cell associated proteins and functional status.";
RL   Nat. Commun. 7:12645.1-12645.14(2016).
//